Harvard Bioscience, Inc.
HBIO
$5.37
-$0.18-3.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -8.06% | -10.60% | -12.24% | -14.41% | -16.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.06% | -10.60% | -12.24% | -14.41% | -16.14% |
| Cost of Revenue | -6.83% | -6.83% | -8.50% | -10.90% | -14.25% |
| Gross Profit | -8.94% | -13.25% | -14.87% | -16.87% | -17.45% |
| SG&A Expenses | -18.28% | -15.60% | -13.53% | -9.44% | -6.63% |
| Depreciation & Amortization | -23.37% | -17.66% | -9.22% | -7.09% | -4.89% |
| Other Operating Expenses | -79.12% | -79.12% | -79.12% | -97.52% | -- |
| Total Operating Expenses | -14.20% | -13.26% | -12.27% | -11.44% | -9.50% |
| Operating Income | 125.58% | 67.70% | 13.07% | -195.69% | -307.94% |
| Income Before Tax | -391.95% | -301.20% | -503.98% | -602.98% | -356.38% |
| Income Tax Expenses | -192.70% | -72.48% | -63.41% | -84.30% | -13.85% |
| Earnings from Continuing Operations | -357.07% | -278.03% | -437.61% | -564.88% | -263.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -357.07% | -278.03% | -437.61% | -564.88% | -263.25% |
| EBIT | 125.58% | 67.70% | 13.07% | -195.69% | -307.94% |
| EBITDA | 269.32% | 99.83% | 7.37% | -54.79% | -79.26% |
| EPS Basic | -350.49% | -271.90% | -427.34% | -549.94% | -256.62% |
| Normalized Basic EPS | 5.77% | 51.24% | -7.11% | -21.95% | -190.52% |
| EPS Diluted | -348.41% | -270.54% | -421.37% | -541.00% | -234.85% |
| Normalized Diluted EPS | 5.93% | 51.09% | -7.31% | -22.16% | -189.86% |
| Average Basic Shares Outstanding | 1.95% | 1.96% | 1.97% | 2.16% | 2.53% |
| Average Diluted Shares Outstanding | 1.49% | 2.42% | 2.43% | 2.63% | 2.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |